Positive FDA feedback for Amsulostat P2b trial
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The FDA's support for the trial design marks a significant milestone, allowing Syntara to advance into late-stage clinical development. Syntara's CEO expressed optimism about the drug's potential and the company's upcoming clinical milestones in the near future.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Story so far
Earlier from Syntara
- Half Year Report and Appendix 4D
- Quarterly Activities/Appendix 4C Cash Flow Report
- Amsulostat and Garvan in MRFF funded pancreatic trial
- SNT-4728 Phase 2 iRBD Parkinsons UK Trial fully recruited
- Skin scarring program to progress on positive Phase1a result
Later from Syntara
- Continuation of trading halt
- $8m placement and share purchase plan
- Share Purchase Plan Offer Booklet
- Results of Share Purchase Plan
- Encouraging SNT-4728 Phase 2 iRBD results
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara